2.89
Schlusskurs vom Vortag:
$2.80
Offen:
$2.8
24-Stunden-Volumen:
145
Relative Volume:
0.01
Marktkapitalisierung:
$26.50M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-23.87M
KGV:
-0.1469
EPS:
-19.67
Netto-Cashflow:
$-47.63M
1W Leistung:
+11.15%
1M Leistung:
+6.64%
6M Leistung:
-12.42%
1J Leistung:
-39.79%
Polypid Ltd Stock (PYPD) Company Profile
Vergleichen Sie PYPD mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
PYPD
Polypid Ltd
|
2.80 | 26.50M | 0 | -23.87M | -47.63M | -19.67 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
500.26 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
610.36 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
649.65 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
258.08 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
256.14 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
2021-09-14 | Eingeleitet | JMP Securities | Mkt Outperform |
2021-07-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
2020-11-24 | Hochstufung | Raymond James | Outperform → Strong Buy |
2020-08-10 | Eingeleitet | Alliance Global Partners | Buy |
2020-07-21 | Eingeleitet | BMO Capital Markets | Outperform |
2020-07-21 | Eingeleitet | Barclays | Overweight |
2020-07-21 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Polypid Ltd Aktie (PYPD) Neueste Nachrichten
PolyPid Ltd. (NASDAQ:PYPD) Short Interest Update - Defense World
PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025 - GlobeNewswire
PolyPid Q1 2025 Earnings Preview: Surgical Outcomes Biopharma Reports May 14 - Stock Titan
Reviewing Baxter International (NYSE:BAX) and PolyPid (NASDAQ:PYPD) - Defense World
PolyPid to Participate in The Citizens Life Sciences Conference - GlobeNewswire
PolyPid to Reveal Next-Gen Surgical Innovation Pipeline at Elite Citizens Life Sciences Conference - Stock Titan
Short Interest in PolyPid Ltd. (NASDAQ:PYPD) Declines By 25.9% - Defense World
What is HC Wainwright’s Estimate for PolyPid Q1 Earnings? - Defense World
What is HC Wainwright’s Forecast for PolyPid Q1 Earnings? - Defense World
H.C. Wainwright maintains Buy on PolyPid stock with $11 target - Investing.com Australia
PolyPid’s (PYPD) Buy Rating Reaffirmed at HC Wainwright - Defense World
H.C. Wainwright maintains Buy on PolyPid stock with $11 target By Investing.com - Investing.com Canada
PolyPid stock touches 52-week low at $2.32 amid market challenges By Investing.com - Investing.com South Africa
PolyPid stock touches 52-week low at $2.32 amid market challenges - Investing.com Australia
Surgical Site Infections Clinical and Non-Clinical Studies, - openPR.com
Barclays Reaffirms Their Hold Rating on PolyPid (PYPD) - The Globe and Mail
Comparing Beta Bionics (NASDAQ:BBNX) and PolyPid (NASDAQ:PYPD) - Defense World
PolyPid Completes Enrollment in Phase 3 Trial for Surgical Infection Prevention - TipRanks
PolyPid Announces Successful Completion of Enrollment in - GlobeNewswire
PolyPid Announces Successful Completion Of Enrollment In Phase 3 Shield II Trial Of D-Plex100 For The Prevention Of Abdominal Colorectal Surgical Site Infections - Marketscreener.com
PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections - Yahoo
Critical Survey: Nyxoah (NASDAQ:NYXH) vs. PolyPid (NASDAQ:PYPD) - Defense World
PolyPid (NASDAQ:PYPD) Stock Price Up 0.7% – Should You Buy? - Defense World
PolyPid to Participate in the 37th Annual ROTH Conference - GlobeNewswire
PolyPid Fireside Chat at ROTH Conference: What New Surgical Innovations Will Management Reveal? - StockTitan
Polypid Ltd to Host Earnings Call - ACCESS Newswire
PolyPid Ltd. to Present at the Q1 Investor Summit Virtual Conference on March 11th, 2025 - The Globe and Mail
PolyPid Ltd. Earnings Call Highlights Promising Prospects - TipRanks
PolyPid Ltd. (NASDAQ:PYPD) Q4 2024 Earnings Call Transcript - Insider Monkey
PolyPid Ltd. Reports Positive Trial Progress and Financial Outlook - TipRanks
PolyPid targets SHIELD II trial completion with top-line results in Q2 2025 - MSN
PolyPid Updates: New Board Appointment and SHIELD II Trial Progress - TipRanks
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results - The Manila Times
PolyPid's Phase 3 Trial Nears Completion: Key Financial Updates Reveal Path to Critical Q2 2025 Results - StockTitan
PolyPid (PYPD) to Release Earnings on Wednesday - Defense World
Head-To-Head Contrast: PolyPid (NASDAQ:PYPD) versus OraSure Technologies (NASDAQ:OSUR) - Defense World
PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Surgical Outcomes Pioneer PolyPid Takes Center Stage at Major Healthcare Conference - StockTitan
PolyPid Ltd. to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Nasdaq
PolyPid (NASDAQ:PYPD) Stock Rating Upgraded by RODMAN&RENSHAW - Defense World
PolyPid to Report Fourth Quarter and Full-Year 2024 - GlobeNewswire
Major Surgical Innovation Updates Expected: PolyPid Sets Critical Q4 Earnings Date - StockTitan
Finanzdaten der Polypid Ltd-Aktie (PYPD)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):